Empowering mental health professionals with peer-reviewed psychiatric research and insights
Page 14
More JCP Articles
Original Research
Effects of the October 7, 2023, Terrorist Attack on PTSD, Depression, Anxiety, and Suicidal Ideation Across Distinct Exposure Groups
September 3, 2025
Prevalence and severity of psychiatric symptoms declined between 1 month and 1 year following the attack; exposure group moderated these changes. Reserve-duty combatants had the highest rates of probable…
Original Research
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
September 3, 2025
Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course. No differences between treatments were observed among responders in at…
Original Research
Five-Year Outcomes of First Suicide Attempts: Lethality, Recurrence, and Mortality
September 1, 2025
Recurrence of suicide attempt occurred in 37.2% of patients, with 27.8% having ≥3 attempts. Alcohol use predicted high-lethality first attempts, and female sex predicted multiple reattempts.
Original Research
Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Clinical Decision Support System for Personalized Depression Treatment Selection and Management
August 27, 2025
This study provides preliminary evidence that longitudinal use of an AI-enabled clinical decision support system can improve outcomes in MDD.
Original Research
N-acetylcysteine for Co-occurring PTSD and Alcohol Use Disorder: A Double-Blind, Randomized Controlled Trial
August 27, 2025
Among individuals with PTSD and alcohol use disorder receiving CBT and either NAC or placebo, both groups had significant reductions in both PTSD symptom severity and alcohol use, with…
Original Research
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
August 25, 2025
In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
Original Research
Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range
August 25, 2025
Levomilnacipran and duloxetine are both potent serotonin reuptake inhibitors at all therapeutic regimens for MDD. Potent norepinephrine reuptake inhibition can be achieved from initiation with levomilnacipran, in contrast to…
Clinical and Practical Psychopharmacology
The Superiority of Clozapine Over SGAs in Patients With Treatment-Resistant Schizophrenia
August 25, 2025
Clozapine is associated with many adverse effects. Given the findings that olanzapine and risperidone may be as good as clozapine in treatment-resistant schizophrenia (TRS), it may be worth trialing…
